Brought to you by 
Qiagen to create companion diagnostic for Pfizer's Phase III non-small cell lung cancer drug candidate
23 Aug 2011
Executive Summary
Qiagen NV (assays) has agreed to help Pfizer Inc. develop a companion molecular diagnostic for use with Pfizer’s Phase III dacomitinib (PF00299804), an oral HER1 (EGFR), HER2, and HER4 tyrosine kinase inhibitor for non-small cell lung cancer (NSCLC).
Deal Industry
- In Vitro Diagnostics
- Pharmaceuticals
-
Research, Analytical Equipment & Supplies
- PCR & Amplification Tools
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Qiagen to create companion diagnostic for Pfizer's Phase III non-small cell lung cancer drug candidate
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice